As of 2024-12-12, the EV/EBITDA ratio of Santhera Pharmaceuticals Holding AG (SANN.SW) is 1.61. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SANN.SW's latest enterprise value is 98.35 mil CHF. SANN.SW's TTM EBITDA according to its financial statements is 61.09 mil CHF. Dividing these 2 quantities gives us the above SANN.SW EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 8.5x - 9.5x | 8.9x |
| Forward P/E multiples | 10.0x - 11.7x | 10.0x |
| Fair Price | 56.94 - 105.22 | 74.80 |
| Upside | 475.8% - 963.9% | 656.3% |
| Date | EV/EBITDA |
| 2024-12-09 | 1.37 |
| 2024-12-06 | 1.34 |
| 2024-12-05 | 1.31 |
| 2024-12-04 | 1.37 |
| 2024-12-03 | 1.37 |
| 2024-12-02 | 1.36 |
| 2024-11-29 | 1.36 |
| 2024-11-28 | 1.37 |
| 2024-11-27 | 1.36 |
| 2024-11-26 | 1.38 |
| 2024-11-25 | 1.38 |
| 2024-11-22 | 1.33 |
| 2024-11-21 | 1.32 |
| 2024-11-20 | 1.38 |
| 2024-11-19 | 1.38 |
| 2024-11-18 | 1.34 |
| 2024-11-15 | 1.38 |
| 2024-11-14 | 1.40 |
| 2024-11-13 | 1.39 |
| 2024-11-12 | 1.40 |
| 2024-11-11 | 1.38 |
| 2024-11-08 | 1.43 |
| 2024-11-07 | 1.45 |
| 2024-11-06 | 1.43 |
| 2024-11-05 | 1.46 |
| 2024-11-04 | 1.43 |
| 2024-11-01 | 1.45 |
| 2024-10-31 | 1.43 |
| 2024-10-30 | 1.46 |
| 2024-10-29 | 1.49 |
| 2024-10-28 | 1.49 |
| 2024-10-25 | 1.49 |
| 2024-10-24 | 1.48 |
| 2024-10-23 | 1.48 |
| 2024-10-22 | 1.48 |
| 2024-10-21 | 1.50 |
| 2024-10-18 | 1.51 |
| 2024-10-17 | 1.49 |
| 2024-10-16 | 1.52 |
| 2024-10-15 | 1.49 |
| 2024-10-14 | 1.49 |
| 2024-10-11 | 1.50 |
| 2024-10-10 | 1.52 |
| 2024-10-09 | 1.50 |
| 2024-10-08 | 1.50 |
| 2024-10-07 | 1.51 |
| 2024-10-04 | 1.49 |
| 2024-10-03 | 1.51 |
| 2024-10-02 | 1.49 |
| 2024-10-01 | 1.50 |